Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Tvardi Therapeutics Q3 2026 Results: Net Loss of $6.12M, Loss Widens

Tvardi Therapeutics reported a net loss of $19.4 million for the nine months ended September 30, 2026, compared to a $10.9 million loss in the prior year period. The company strengthened its liquidity by raising $13.3 million through an at-the-market equity facility, ending the quarter with $22.3 million in cash and cash equivalents.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-6.1-5.5
EPS (diluted, $ a share)$-0.48$-0.59

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: TVRD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Tvardi Therapeutics, Inc.: key numbers

Share price
$1.10Close, Nov 16
Market cap
$14.7M
Shares outstanding
13.36MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Tvardi Therapeutics, Inc.

All →
7:06 AM ET 8-K
Financial Results

Tvardi Therapeutics Financial Results

Tvardi Therapeutics reported third quarter 2026 financial results and provided updates on its STAT3 inhibitor pipeline, including plans to advance TTI-109 into clinical development for ulcerative colitis in 2027. The company also confirmed it expects a topline readout for its Phase 1b/2 study of TTI-101 in hepatocellular carcinoma in early Q1 2027.

Term
Q3 2026

“We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps.”

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.